Buy One Get One free -Llimited Time Offer X
Nebitroy H is a prescription drug, available for use as Tablet. Nebitroy H also has some secondary and off-label uses. These are listed below.
Medical history of the patient along with age and gender determines the dosage of Nebitroy H. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Nebitroy H as well, which are listed below. Usually, these side effects of Nebitroy H go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Nebitroy H's effect is Safe during pregnancy and Safe for lactating mothers. It is important to know if Nebitroy H has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Nebitroy H related warnings section.
Nebitroy H can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Nebitroy H in conditions like Diabetes, Asthma, COPD (Chronic Obstructive Pulmonary Disease). The section on Nebitroy H contraindications lists all such conditions.
Drug reaction of Nebitroy H with other medicines has been reported. Refer to the list below for further details.
In addition to the above precautions for Nebitroy H, it is important to know that it is not safe while driving, and is not habit-forming.
Nebitroy H is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Based on research, the following side effects have been observed when Nebitroy H is used -
Severe
Moderate
Mild
Is the use of Nebitroy H safe for pregnant women?
There are no side effects of Nebitroy H in pregnant women.
Is the use of Nebitroy H safe during breastfeeding?
Nebitroy H is completely safe for breastfeeding women.
What is the effect of Nebitroy H on the Kidneys?
Nebitroy H rarely harms the kidneys.
What is the effect of Nebitroy H on the Liver?
Nebitroy H may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Nebitroy H on the Heart?
Nebitroy H may have mild side effects on the heart. Most people will never see any effect on the heart.
Nebitroy H should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Nebitroy H unless your doctor advises you to do so -
Is this Nebitroy H habit forming or addictive?
Nebitroy H does not cause addiction.
Interaction between Food and Nebitroy H
Some foods when eaten with Nebitroy H can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Nebitroy H
Taking Nebitroy H with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bystolic® (nebivolol)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 149-151
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 896-897
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Hydrochlorothiazide
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 582-586
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 446-448